FDA Approves First Gene Therapy (Lenmeldy) for Metachromatic Leukodystrophy in Children

Поділитися
Вставка
  • Опубліковано 1 лис 2024

КОМЕНТАРІ • 6

  • @MuthuPrasanth-rw5gv
    @MuthuPrasanth-rw5gv 22 дні тому

    This medicine india coming. What date

  • @MuthuPrasanth-rw5gv
    @MuthuPrasanth-rw5gv 19 днів тому

    Sir i want medicine. So please response sir 🙏🙏🙏. But. Iam indian my. Country coming what date sir

  • @rachanaarasan8505
    @rachanaarasan8505 4 місяці тому

    May i know the address siri want give my son treatment please responce

    • @WorldOfEduPharma
      @WorldOfEduPharma  4 місяці тому

      In terms of availability, Lenmeldy has been approved by the FDA in the United States and is also known as Libmeldy in Europe, where it has received approval in several countries, including the UK, Germany, France, Italy, Denmark, Norway, and the Netherlands. The cost of treatment in Europe ranges from $2.4 million to $3.1 million, with varying levels of reimbursement across different countries​.
      I'm not able to provide a specific address for treatment, but I recommend contacting a pediatric neurologist or geneticist who specializes in treating metachromatic leukodystrophy (MLD). They can provide guidance and information on where to find the best treatment options for your son. You can also visit the FDA's official website or contact a local healthcare provider for more detailed information. Best wishes for your son's treatment and health.

  • @alpeshraiyani744
    @alpeshraiyani744 5 місяців тому

    Helloo